Facing clinical challenges,continuously deepening CAR-T treatment for T-cell tumors:

1.Autologous CD7 CAR-T for R/R T-ALL/LBL:One month after CAR-T infusion,the complete remission(CR)rate with MRD negativity was 85%.The median follow-up time was 9.2 months(range 0.3-24.0 months),among which,out of the 13 patients who underwent transplantation,MRD negative CR was achieved.No major infectious events were observed in all patients.

2.Donor-derived CD7 CAR-T for R/R T-ALL/LBL:24 months post-treatment,the objective response(OR)rate and CR rate were 95%(19/20 cases)and 85%(17/20 cases)respectively,with 24-month progression-free survival(PFS)rate and overall survival(OS)rate of 36.8%and 42.3%.The median PFS and OS were 11.0 months and 18.0 months respectively.The results suggest that donor-derived CD7 CAR-T cell therapy may offer long-term survival benefits for patients with R/R T-ALL,with controllable safety.

3.Donor-derived CD5 CAR-T for R/R T-ALL/LBL:Included 14 R/R T-ALL patients,comprising those with low expression/loss of expression of CD7(n=3)and low expression post-CAR-T treatment(n=7).Twelve patients achieved complete remission(CR)on day 30,with a median follow-up time of 10.9 months(range 1.3-16.7 months).